New viral vaccines for dermatologic disease

Urman, Christine Orlova; Gottlieb, Alice B.

doi:10.1016/j.jaad.2007.07.051

Cited by 18 publications

(30 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Together, these events help to attain a sort of immune anergy that explains the general lack of local inflammation and the poor immune response to the virus. However, most HPV infections are usually transient [31], and clinically significant genital warts develop in only about 1 % of individuals infected with HPV types 6 and 11 [32]. Approximately 70 % of new infections resolve within 1 year, and 91 % within 2 years [31].…”

Section: The Hpv Life Cyclementioning

confidence: 99%

“…Approximately 70 % of new infections resolve within 1 year, and 91 % within 2 years [31]. Only 25 % of all women infected with high-risk HPV develop cervical intraepithelial neoplasia, and less than 1 % will develop invasive cervical cancer [32]. The humoral immune response after HPV infection is relatively poor, probably because the virus is not cytolytic and does not have a blood-borne stage [32,33].…”

Section: The Hpv Life Cyclementioning

confidence: 99%

“…Only 25 % of all women infected with high-risk HPV develop cervical intraepithelial neoplasia, and less than 1 % will develop invasive cervical cancer [32]. The humoral immune response after HPV infection is relatively poor, probably because the virus is not cytolytic and does not have a blood-borne stage [32,33]. HPV infections are mostly cleared by cell-mediated immunity in which dendritic cells (DCs), T helper (Th) cells and Tc cells play predominant roles [32].…”

Section: The Hpv Life Cyclementioning

confidence: 99%

“…The humoral immune response after HPV infection is relatively poor, probably because the virus is not cytolytic and does not have a blood-borne stage [32,33]. HPV infections are mostly cleared by cell-mediated immunity in which dendritic cells (DCs), T helper (Th) cells and Tc cells play predominant roles [32].…”

Section: The Hpv Life Cyclementioning

confidence: 99%

See 3 more Smart Citations

Human papillomavirus: current status and issues of vaccination

2013

View full text Add to dashboard Cite

An association between human papillomavirus (HPV) infection and the development of cervical cancer was initially suggested over 30 years ago, and today there is clear evidence that certain subtypes of HPV are the causative agents of such malignancies. Papillomaviruses make up a vast family that comprises hundreds of different viruses. These viruses infect epithelia in humans and animals and cause benign hyperproliferative lesions, commonly called warts or papillomas, which can occasionally progress to squamous cell cancer. HPV infections are considered the most common among sexually transmitted diseases. One of the most prevalent cancer types induced by HPV (mostly types 16 and 18) is cervical cancer. Vaccination is the most effective means of preventing this infectious disease. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective in providing protection from infection in almost 100 % of cases. VLP vaccines of HPV are subunit vaccines consisting only of the major viral capsid protein of HPV. There are two types of vaccine available: bivalent vaccine (against HPV-16/18) and quadrivalent vaccine (against HPV-6/11/16/18). Second-generation prophylactic HPV vaccines, currently in clinical trials, may hold several merits over the current bivalent and quadrivalent vaccines, such as protection against additional oncogenic HPV types, less dependence on cold-chain storage and distribution, and non-invasive methods of delivery.

show abstract

Section: The Hpv Life Cyclementioning

confidence: 99%

Section: The Hpv Life Cyclementioning

confidence: 99%

Section: The Hpv Life Cyclementioning

confidence: 99%

Section: The Hpv Life Cyclementioning

confidence: 99%

See 2 more Smart Citations

Human papillomavirus: current status and issues of vaccination

2013

View full text Add to dashboard Cite

show abstract

“…Ainsi dans un objectif de réactivation de l'immunité spécifique anti-VZV chez les sujets âgés, plusieurs études ont été menées sur l'utilisation de vaccins à virus VZV atténué ou tué. Toutes ont observé un effet bénéfique sur la réponse immune et ce avec une très bonne tolérance [45]. [47], il serait important de favoriser l'accès au vaccin au plus grand nombre [48].…”

Section: Préventionunclassified